Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human Apob100 x CETP transgenic mice

Steven H. Zuckerman, Glenn F. Evans, Judi A. Schelm, Patrick I. Eacho, George Sandusky

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The murine double transgenic mouse expressing both human apoB100 and cholesteryl ester transfer protein (CETP), has been used as a model to understand the effects mediated by various therapeutic modalities on serum lipoproteins and on atherosclerotic lesion progression. In the present study the effects of estrogen therapy on serum lipoproteins were investigated after mice were placed on an atherosclerotic diet. The daily oral administration of 20 or 100 μg/kg of 17 α-ethinyl estradiol resulted in a significant, dose- dependent increase in LDL cholesterol over a 20-week regimen. These differences were apparent by 6 weeks and further increases were observed through the 20-week period. Although CETP did result in a reduction in total HDL, estrogen did not have any impact on the amount of CETP activity associated with the HDL particles. The significant increase in LDL cholesterol was associated with increases in the amount of apoB 100 and B48 and apoE-containing particles. Hepatic apoB message levels, however, were not different between the experimental groups. Although the extent of atherosclerotic lesions was modest, <0.5% of the aortic surface area in the vehicle group, the high-dose estrogen group, showed an increase in lesion area consistent with the elevation in LDL cholesterol. These lesions, primarily restricted to the aortic root and aortic semilunar valves, were more intensely stained with Oil Red O in the high-dose estrogen group when compared with the vehicle controls.

Original languageEnglish (US)
Pages (from-to)1476-1483
Number of pages8
JournalArteriosclerosis, thrombosis, and vascular biology
Volume19
Issue number6
DOIs
StatePublished - Jun 1999

Fingerprint

Cholesterol Ester Transfer Proteins
Foam Cells
LDL Cholesterol
Transgenic Mice
Estrogens
Lipoproteins
Apolipoprotein B-100
Ethinyl Estradiol
Apolipoproteins B
Apolipoproteins E
Serum
Aortic Valve
Oral Administration
Diet
Liver
Therapeutics

Keywords

  • Apoproteins
  • Cholesterol
  • Estrogen
  • Lipoproteins
  • Transgenic

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human Apob100 x CETP transgenic mice. / Zuckerman, Steven H.; Evans, Glenn F.; Schelm, Judi A.; Eacho, Patrick I.; Sandusky, George.

In: Arteriosclerosis, thrombosis, and vascular biology, Vol. 19, No. 6, 06.1999, p. 1476-1483.

Research output: Contribution to journalArticle

@article{95d7265e99ae4fc3bb787a7bb4df8feb,
title = "Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human Apob100 x CETP transgenic mice",
abstract = "The murine double transgenic mouse expressing both human apoB100 and cholesteryl ester transfer protein (CETP), has been used as a model to understand the effects mediated by various therapeutic modalities on serum lipoproteins and on atherosclerotic lesion progression. In the present study the effects of estrogen therapy on serum lipoproteins were investigated after mice were placed on an atherosclerotic diet. The daily oral administration of 20 or 100 μg/kg of 17 α-ethinyl estradiol resulted in a significant, dose- dependent increase in LDL cholesterol over a 20-week regimen. These differences were apparent by 6 weeks and further increases were observed through the 20-week period. Although CETP did result in a reduction in total HDL, estrogen did not have any impact on the amount of CETP activity associated with the HDL particles. The significant increase in LDL cholesterol was associated with increases in the amount of apoB 100 and B48 and apoE-containing particles. Hepatic apoB message levels, however, were not different between the experimental groups. Although the extent of atherosclerotic lesions was modest, <0.5{\%} of the aortic surface area in the vehicle group, the high-dose estrogen group, showed an increase in lesion area consistent with the elevation in LDL cholesterol. These lesions, primarily restricted to the aortic root and aortic semilunar valves, were more intensely stained with Oil Red O in the high-dose estrogen group when compared with the vehicle controls.",
keywords = "Apoproteins, Cholesterol, Estrogen, Lipoproteins, Transgenic",
author = "Zuckerman, {Steven H.} and Evans, {Glenn F.} and Schelm, {Judi A.} and Eacho, {Patrick I.} and George Sandusky",
year = "1999",
month = "6",
doi = "10.1161/01.ATV.19.6.1476",
language = "English (US)",
volume = "19",
pages = "1476--1483",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human Apob100 x CETP transgenic mice

AU - Zuckerman, Steven H.

AU - Evans, Glenn F.

AU - Schelm, Judi A.

AU - Eacho, Patrick I.

AU - Sandusky, George

PY - 1999/6

Y1 - 1999/6

N2 - The murine double transgenic mouse expressing both human apoB100 and cholesteryl ester transfer protein (CETP), has been used as a model to understand the effects mediated by various therapeutic modalities on serum lipoproteins and on atherosclerotic lesion progression. In the present study the effects of estrogen therapy on serum lipoproteins were investigated after mice were placed on an atherosclerotic diet. The daily oral administration of 20 or 100 μg/kg of 17 α-ethinyl estradiol resulted in a significant, dose- dependent increase in LDL cholesterol over a 20-week regimen. These differences were apparent by 6 weeks and further increases were observed through the 20-week period. Although CETP did result in a reduction in total HDL, estrogen did not have any impact on the amount of CETP activity associated with the HDL particles. The significant increase in LDL cholesterol was associated with increases in the amount of apoB 100 and B48 and apoE-containing particles. Hepatic apoB message levels, however, were not different between the experimental groups. Although the extent of atherosclerotic lesions was modest, <0.5% of the aortic surface area in the vehicle group, the high-dose estrogen group, showed an increase in lesion area consistent with the elevation in LDL cholesterol. These lesions, primarily restricted to the aortic root and aortic semilunar valves, were more intensely stained with Oil Red O in the high-dose estrogen group when compared with the vehicle controls.

AB - The murine double transgenic mouse expressing both human apoB100 and cholesteryl ester transfer protein (CETP), has been used as a model to understand the effects mediated by various therapeutic modalities on serum lipoproteins and on atherosclerotic lesion progression. In the present study the effects of estrogen therapy on serum lipoproteins were investigated after mice were placed on an atherosclerotic diet. The daily oral administration of 20 or 100 μg/kg of 17 α-ethinyl estradiol resulted in a significant, dose- dependent increase in LDL cholesterol over a 20-week regimen. These differences were apparent by 6 weeks and further increases were observed through the 20-week period. Although CETP did result in a reduction in total HDL, estrogen did not have any impact on the amount of CETP activity associated with the HDL particles. The significant increase in LDL cholesterol was associated with increases in the amount of apoB 100 and B48 and apoE-containing particles. Hepatic apoB message levels, however, were not different between the experimental groups. Although the extent of atherosclerotic lesions was modest, <0.5% of the aortic surface area in the vehicle group, the high-dose estrogen group, showed an increase in lesion area consistent with the elevation in LDL cholesterol. These lesions, primarily restricted to the aortic root and aortic semilunar valves, were more intensely stained with Oil Red O in the high-dose estrogen group when compared with the vehicle controls.

KW - Apoproteins

KW - Cholesterol

KW - Estrogen

KW - Lipoproteins

KW - Transgenic

UR - http://www.scopus.com/inward/record.url?scp=0033023371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033023371&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.19.6.1476

DO - 10.1161/01.ATV.19.6.1476

M3 - Article

C2 - 10364078

AN - SCOPUS:0033023371

VL - 19

SP - 1476

EP - 1483

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 6

ER -